Benznidazole
- Generic Name
- Benznidazole
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H12N4O3
- CAS Number
- 22994-85-0
- Unique Ingredient Identifier
- YC42NRJ1ZD
- Background
Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
- Indication
For use in the treatment of Chagas disease in children 2-12 years of age .
- Associated Conditions
- Chagas' Disease caused by Typanosoma cruzi
- Associated Therapies
- -
Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2015-05-27
- Target Recruit Count
- 52
- Registration Number
- NCT01755403
- Locations
- 🇪🇸
International Health Department, Hospital Clinic, Barcelona, Barcelona, Cataluña, Spain
New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2016-08-22
- Target Recruit Count
- 63
- Registration Number
- NCT01755377
- Locations
- 🇪🇸
International Health Department, Hospital Clinic, Barcelona, Barcelona, Cataluña, Spain
Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 220
- Registration Number
- NCT01678599
- Locations
- 🇧🇴
Medicin Sans Frontièrs (MSF), Aiquile, Bolivia
Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease
- Conditions
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 230
- Registration Number
- NCT01489228
- Locations
- 🇧🇴
Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas, Tarija, Bolivia
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT01377480
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2013-09-10
- Target Recruit Count
- 78
- Registration Number
- NCT01162967
- Locations
- 🇪🇸
International Health Unit Drassanes, Barcelona, Spain
🇪🇸Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸International Health Unit Metropolitana Nord, Santa Coloma, Barcelona, Spain
Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
- Target Recruit Count
- 37
- Registration Number
- NCT00699387
- Locations
- 🇦🇷
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires, Buenos Aires, Argentina
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
- Conditions
- Interventions
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 2854
- Registration Number
- NCT00123916
- Locations
- 🇨🇴
BENEFIT Investigational Site, San Gil, Santander, Colombia
🇸🇻BENEFIT Ivestigational Site, San Salvador, El Salvador
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.